Why is Glaxosmi. Pharma falling/rising?

As of 04-Sep, Glaxosmithkline Pharmaceuticals Ltd is experiencing a price increase, currently at 2,835.40, reflecting a rise of 59.35 or 2.14%. The stock has outperformed its sector today by 2.29% and has shown a consecutive gain over the last two days, accumulating a total return of 2.85%. Despite a slight decline of 1.04% over the past month, the stock has performed well year-to-date with a return of 26.20%. The company benefits from high management efficiency, indicated by a return on equity (ROE) of 42.32%, and maintains a low debt-to-equity ratio, which supports its financial stability.
In the broader market context, the stock's short-term performance of +3.01% over the past week surpasses the Sensex's gain of +0.80%, indicating a stronger relative performance. However, the stock's one-month return of -1.04% is worse than the benchmark's -0.37%, suggesting some recent weakness. Additionally, there has been a decline in investor participation, with delivery volume decreasing by 15.45% against the five-day average, which may indicate reduced trading interest. Overall, while the stock is currently rising, the mixed performance over different time frames and declining participation could pose challenges ahead.